Incretin-Based Drugs Market By Drug Class (GLP-1 receptor agonists, DPP-4 inhibitors), By Route of Administration (Parenteral, Oral), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2023-2032
The global incretin-based drugs market was valued at $34.3 billion in 2022, and is projected to reach $73.9 billion by 2032, registering a CAGR of 7.9% from 2023 to 2032. Incretins are a group of gastrointestinal polypeptides that control insulin production in pancreatic beta cells. Incretins are essential for the regulation of insulin production and the metabolism of glucose in the body, especially after food intake. Glucagon-like peptide-1 or GLP-1 is a hormone secreted by the digestive tract in response to food. It stimulates insulin secretion from the pancreatic beta cells and helps to lower blood glucose levels after meals. These incretins release insulin not only when blood glucose levels rise but also when glucose levels are expected to rise, helping to regulate glucose levels. However, these incretin hormones are rapidly broken down by the enzyme dipeptidyl peptidase-4 (DPP-4), which decreases their effectiveness and duration of action in the body.
To enhance the action of incretins in managing type 2 diabetes, pharmaceutical approaches include the use of DPP-4 inhibitors and GLP-1 analogues. The DPP-4 inhibitors work by blocking DPP-4 activity. These drugs increase the levels of circulating glucagon-like peptides (GLP-1) and gastric inhibitory peptide (GIP). These hormones have a longer-lasting effect on insulin secretion and glucose regulation. On the other hand, synthetic GLP-1 drugs are GLP-1 transporters that are more tolerant to DPP-4 degradation. They work by mimicking the action of natural GLP-1. These drugs increase insulin release, inhibit glucagon secretion, slow gastric emptying, and reduce appetite.
The growth of incretin-based drugs market is mainly attributed to the high prevalence of type 2 diabetes population around the globe. Type 2 diabetes is a condition in which blood sugar levels are too high and the body is not able to produce enough insulin. The number of people with type 2 diabetes is on the rise, due to the rise in obesity around the world. Diabetes mellitus (Type 2) is currently treated using incretin-based drugs. These drugs control glucose metabolism in a variety of ways, are associated with low levels of hypoglycemia, and either do not affect body weight or do not stimulate weight loss. Thus have a huge demand in the treatment of this condition, which propels the growth of the incretin-based drugs market.
In addition, incretin-based drugs have shown promising results in weight loss or weight neutrality. This makes them attractive to a wider patient base interested in obesity management. Furthermore, ongoing R&D efforts to enhance the effectiveness, safety, and delivery mechanisms of the incretin-based therapies have also contributed to market expansion. The growing knowledge of the biology behind incretin and its impact on various metabolic disorders continue to drive innovation. This is anticipated to drive the market for incretin-based drugs in coming years.
However, the high cost of the treatment and regulatory challenges may hamper market growth to some extent. Incretin based drugs are usually more expensive than traditional diabetes drugs. Cost becomes a major issue, especially in areas where healthcare costs are high, which may limit access to these drugs. Also, the market is affected by stringent regulations and approval procedures by regulatory bodies such as the Food and Drug Administration (FDA) in the U.S. and the European Medicines Agency (EMA) in Europe. Delays or complexity in the approval of new drugs or indications may impede market growth. The incretin-based drugs market is segmented on the basis of drug class, route of administration, distribution channel, and region. On the basis of drug class, the market is divided into GLP-1 receptor agonists and DPP-4 inhibitors. On the basis of route of administration, the market is classified into oral and parenteral. By distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major players profiled in this report are Eli Lilly and Company., Merck & Co., Inc., GlaxoSmithKline plc, Sanofi, Sun Pharmaceutical Industries Ltd., Lupin, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, AstraZeneca plc and Takeda Pharmaceutical Company Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the incretin-based drugs market analysis from 2022 to 2032 to identify the prevailing incretin-based drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the incretin-based drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global incretin-based drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
GLP-1 receptor agonists
DPP-4 inhibitors
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Eli Lilly and Company.
Takeda Pharmaceutical Company Ltd.
Lupin
Novartis AG
Merck & Co., Inc.
Sun Pharmaceutical Industries Ltd.
Boehringer Ingelheim International GmbH
Sanofi
Novo Nordisk A/S
AstraZeneca plc
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rising prevalence of type-2 diabetes
- 3.4.1.2. Recent product approvals and product launches in the market
- 3.4.1.3. Recent advancement in Incretin-Based Pharmacotherapies
- 3.4.2. Restraints
- 3.4.2.1. High cost of incretin-based drugs
- 3.4.2.2. Stringent regulations related to medications
- 3.4.3. Opportunities
- 3.4.3.1. Surge in research and development in incretin-based drugs
- CHAPTER 4: INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. GLP-1 receptor agonists
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. DPP-4 inhibitors
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- CHAPTER 5: INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Parenteral
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Oral
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- CHAPTER 6: INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Drug Stores and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Online Providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: INCRETIN-BASED DRUGS MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Drug Class
- 7.2.3. Market size and forecast, by Route of Administration
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Market size and forecast, by Drug Class
- 7.2.5.1.2. Market size and forecast, by Route of Administration
- 7.2.5.1.3. Market size and forecast, by Distribution Channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Market size and forecast, by Drug Class
- 7.2.5.2.2. Market size and forecast, by Route of Administration
- 7.2.5.2.3. Market size and forecast, by Distribution Channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Market size and forecast, by Drug Class
- 7.2.5.3.2. Market size and forecast, by Route of Administration
- 7.2.5.3.3. Market size and forecast, by Distribution Channel
- 7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Drug Class
- 7.3.3. Market size and forecast, by Route of Administration
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Market size and forecast, by Drug Class
- 7.3.5.1.2. Market size and forecast, by Route of Administration
- 7.3.5.1.3. Market size and forecast, by Distribution Channel
- 7.3.5.2. France
- 7.3.5.2.1. Market size and forecast, by Drug Class
- 7.3.5.2.2. Market size and forecast, by Route of Administration
- 7.3.5.2.3. Market size and forecast, by Distribution Channel
- 7.3.5.3. UK
- 7.3.5.3.1. Market size and forecast, by Drug Class
- 7.3.5.3.2. Market size and forecast, by Route of Administration
- 7.3.5.3.3. Market size and forecast, by Distribution Channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Market size and forecast, by Drug Class
- 7.3.5.4.2. Market size and forecast, by Route of Administration
- 7.3.5.4.3. Market size and forecast, by Distribution Channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Market size and forecast, by Drug Class
- 7.3.5.5.2. Market size and forecast, by Route of Administration
- 7.3.5.5.3. Market size and forecast, by Distribution Channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Market size and forecast, by Drug Class
- 7.3.5.6.2. Market size and forecast, by Route of Administration
- 7.3.5.6.3. Market size and forecast, by Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Drug Class
- 7.4.3. Market size and forecast, by Route of Administration
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Market size and forecast, by Drug Class
- 7.4.5.1.2. Market size and forecast, by Route of Administration
- 7.4.5.1.3. Market size and forecast, by Distribution Channel
- 7.4.5.2. China
- 7.4.5.2.1. Market size and forecast, by Drug Class
- 7.4.5.2.2. Market size and forecast, by Route of Administration
- 7.4.5.2.3. Market size and forecast, by Distribution Channel
- 7.4.5.3. India
- 7.4.5.3.1. Market size and forecast, by Drug Class
- 7.4.5.3.2. Market size and forecast, by Route of Administration
- 7.4.5.3.3. Market size and forecast, by Distribution Channel
- 7.4.5.4. Australia
- 7.4.5.4.1. Market size and forecast, by Drug Class
- 7.4.5.4.2. Market size and forecast, by Route of Administration
- 7.4.5.4.3. Market size and forecast, by Distribution Channel
- 7.4.5.5. South Korea
- 7.4.5.5.1. Market size and forecast, by Drug Class
- 7.4.5.5.2. Market size and forecast, by Route of Administration
- 7.4.5.5.3. Market size and forecast, by Distribution Channel
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Market size and forecast, by Drug Class
- 7.4.5.6.2. Market size and forecast, by Route of Administration
- 7.4.5.6.3. Market size and forecast, by Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Drug Class
- 7.5.3. Market size and forecast, by Route of Administration
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Market size and forecast, by Drug Class
- 7.5.5.1.2. Market size and forecast, by Route of Administration
- 7.5.5.1.3. Market size and forecast, by Distribution Channel
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Market size and forecast, by Drug Class
- 7.5.5.2.2. Market size and forecast, by Route of Administration
- 7.5.5.2.3. Market size and forecast, by Distribution Channel
- 7.5.5.3. South Africa
- 7.5.5.3.1. Market size and forecast, by Drug Class
- 7.5.5.3.2. Market size and forecast, by Route of Administration
- 7.5.5.3.3. Market size and forecast, by Distribution Channel
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Market size and forecast, by Drug Class
- 7.5.5.4.2. Market size and forecast, by Route of Administration
- 7.5.5.4.3. Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product mapping of top 10 player
- 8.4. Competitive dashboard
- 8.5. Competitive heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Eli Lilly and Company.
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. Merck & Co., Inc.
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.3. Takeda Pharmaceutical Company Ltd.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.4. AstraZeneca plc
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. Sanofi
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.6. Sun Pharmaceutical Industries Ltd.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.7. Lupin
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.8. Novo Nordisk A/S
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. Boehringer Ingelheim International GmbH
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.10. Novartis AG
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- LIST OF TABLES
- TABLE 01. GLOBAL INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 02. INCRETIN-BASED DRUGS MARKET FOR GLP-1 RECEPTOR AGONISTS, BY REGION, 2022-2032 ($MILLION)
- TABLE 03. INCRETIN-BASED DRUGS MARKET FOR DPP-4 INHIBITORS, BY REGION, 2022-2032 ($MILLION)
- TABLE 04. GLOBAL INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 05. INCRETIN-BASED DRUGS MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
- TABLE 06. INCRETIN-BASED DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
- TABLE 07. GLOBAL INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 08. INCRETIN-BASED DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
- TABLE 09. INCRETIN-BASED DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
- TABLE 10. INCRETIN-BASED DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 11. INCRETIN-BASED DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
- TABLE 12. NORTH AMERICA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 13. NORTH AMERICA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 14. NORTH AMERICA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 15. NORTH AMERICA INCRETIN-BASED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 16. U.S. INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 17. U.S. INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 18. U.S. INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 19. CANADA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 20. CANADA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 21. CANADA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 22. MEXICO INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 23. MEXICO INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 24. MEXICO INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 25. EUROPE INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 26. EUROPE INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 27. EUROPE INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 28. EUROPE INCRETIN-BASED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 29. GERMANY INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 30. GERMANY INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 31. GERMANY INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 32. FRANCE INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 33. FRANCE INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 34. FRANCE INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 35. UK INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 36. UK INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 37. UK INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 38. ITALY INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 39. ITALY INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 40. ITALY INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 41. SPAIN INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 42. SPAIN INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 43. SPAIN INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 44. REST OF EUROPE INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 45. REST OF EUROPE INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 46. REST OF EUROPE INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 47. ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 48. ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 49. ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 50. ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 51. JAPAN INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 52. JAPAN INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 53. JAPAN INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 54. CHINA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 55. CHINA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 56. CHINA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 57. INDIA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 58. INDIA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 59. INDIA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 60. AUSTRALIA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 61. AUSTRALIA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 62. AUSTRALIA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 63. SOUTH KOREA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 64. SOUTH KOREA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 65. SOUTH KOREA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 66. REST OF ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 67. REST OF ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 68. REST OF ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 69. LAMEA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 70. LAMEA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 71. LAMEA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 72. LAMEA INCRETIN-BASED DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 73. BRAZIL INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 74. BRAZIL INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 75. BRAZIL INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 76. SAUDI ARABIA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 77. SAUDI ARABIA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 78. SAUDI ARABIA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 79. SOUTH AFRICA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 80. SOUTH AFRICA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 81. SOUTH AFRICA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 82. REST OF LAMEA INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
- TABLE 83. REST OF LAMEA INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 84. REST OF LAMEA INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 85. ELI LILLY AND COMPANY.: KEY EXECUTIVES
- TABLE 86. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
- TABLE 87. ELI LILLY AND COMPANY.: PRODUCT SEGMENTS
- TABLE 88. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
- TABLE 89. ELI LILLY AND COMPANY.: KEY STRATERGIES
- TABLE 90. MERCK & CO., INC.: KEY EXECUTIVES
- TABLE 91. MERCK & CO., INC.: COMPANY SNAPSHOT
- TABLE 92. MERCK & CO., INC.: PRODUCT SEGMENTS
- TABLE 93. MERCK & CO., INC.: PRODUCT PORTFOLIO
- TABLE 94. TAKEDA PHARMACEUTICAL COMPANY LTD.: KEY EXECUTIVES
- TABLE 95. TAKEDA PHARMACEUTICAL COMPANY LTD.: COMPANY SNAPSHOT
- TABLE 96. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT SEGMENTS
- TABLE 97. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT PORTFOLIO
- TABLE 98. ASTRAZENECA PLC: KEY EXECUTIVES
- TABLE 99. ASTRAZENECA PLC: COMPANY SNAPSHOT
- TABLE 100. ASTRAZENECA PLC: PRODUCT SEGMENTS
- TABLE 101. ASTRAZENECA PLC: PRODUCT PORTFOLIO
- TABLE 102. ASTRAZENECA PLC: KEY STRATERGIES
- TABLE 103. SANOFI: KEY EXECUTIVES
- TABLE 104. SANOFI: COMPANY SNAPSHOT
- TABLE 105. SANOFI: PRODUCT SEGMENTS
- TABLE 106. SANOFI: PRODUCT PORTFOLIO
- TABLE 107. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 108. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 109. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
- TABLE 110. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 111. LUPIN: KEY EXECUTIVES
- TABLE 112. LUPIN: COMPANY SNAPSHOT
- TABLE 113. LUPIN: PRODUCT SEGMENTS
- TABLE 114. LUPIN: PRODUCT PORTFOLIO
- TABLE 115. NOVO NORDISK A/S: KEY EXECUTIVES
- TABLE 116. NOVO NORDISK A/S: COMPANY SNAPSHOT
- TABLE 117. NOVO NORDISK A/S: PRODUCT SEGMENTS
- TABLE 118. NOVO NORDISK A/S: PRODUCT PORTFOLIO
- TABLE 119. NOVO NORDISK A/S: KEY STRATERGIES
- TABLE 120. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
- TABLE 121. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
- TABLE 122. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
- TABLE 123. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
- TABLE 124. NOVARTIS AG: KEY EXECUTIVES
- TABLE 125. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 126. NOVARTIS AG: PRODUCT SEGMENTS
- TABLE 127. NOVARTIS AG: PRODUCT PORTFOLIO
- LIST OF FIGURES
- FIGURE 01. INCRETIN-BASED DRUGS MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF INCRETIN-BASED DRUGS MARKET,2022-2032
- FIGURE 03. TOP IMPACTING FACTORS IN INCRETIN-BASED DRUGS MARKET (2022 TO 2032)
- FIGURE 04. TOP INVESTMENT POCKETS IN INCRETIN-BASED DRUGS MARKET (2023-2032)
- FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
- FIGURE 06. LOW THREAT OF NEW ENTRANTS
- FIGURE 07. LOW THREAT OF SUBSTITUTES
- FIGURE 08. LOW INTENSITY OF RIVALRY
- FIGURE 09. LOW BARGAINING POWER OF BUYERS
- FIGURE 10. GLOBAL INCRETIN-BASED DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11. INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS, 2022 AND 2032(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF INCRETIN-BASED DRUGS MARKET FOR GLP-1 RECEPTOR AGONISTS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF INCRETIN-BASED DRUGS MARKET FOR DPP-4 INHIBITORS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022 AND 2032(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF INCRETIN-BASED DRUGS MARKET FOR PARENTERAL, BY COUNTRY 2022 AND 2032(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF INCRETIN-BASED DRUGS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
- FIGURE 17. INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF INCRETIN-BASED DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF INCRETIN-BASED DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF INCRETIN-BASED DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 21. INCRETIN-BASED DRUGS MARKET BY REGION, 2022 AND 2032(%)
- FIGURE 22. U.S. INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 23. CANADA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 24. MEXICO INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 25. GERMANY INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 26. FRANCE INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 27. UK INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 28. ITALY INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 29. SPAIN INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 30. REST OF EUROPE INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 31. JAPAN INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 32. CHINA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 33. INDIA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 34. AUSTRALIA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 35. SOUTH KOREA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 36. REST OF ASIA-PACIFIC INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 37. BRAZIL INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 38. SAUDI ARABIA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 39. SOUTH AFRICA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 40. REST OF LAMEA INCRETIN-BASED DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 41. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
- FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
- FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
- FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 45. COMPETITIVE DASHBOARD
- FIGURE 46. COMPETITIVE HEATMAP: INCRETIN-BASED DRUGS MARKET
- FIGURE 47. TOP PLAYER POSITIONING, 2022
- FIGURE 48. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 49. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 50. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 51. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 52. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 53. TAKEDA PHARMACEUTICAL COMPANY LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 54. TAKEDA PHARMACEUTICAL COMPANY LTD.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 55. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
- FIGURE 56. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 57. SANOFI: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 58. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 59. SANOFI: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 60. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 61. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 62. LUPIN: NET SALES, 2020-2022 ($MILLION)
- FIGURE 63. LUPIN: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 64. NOVO NORDISK A/S: NET SALES, 2020-2022 ($MILLION)
- FIGURE 65. NOVO NORDISK A/S: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 66. NOVO NORDISK A/S: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 67. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION)
- FIGURE 68. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 69. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 70. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
- FIGURE 71. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 72. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook